Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (12) Arrow Down
Filter Results: (12) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (139)
    • Faculty Publications  (12)

    Show Results For

    • All HBS Web  (139)
      • Faculty Publications  (12)

      Precision MedicineRemove Precision Medicine →

      Page 1 of 12 Results

      Are you looking for?

      →Search All HBS Web
      • 2023
      • Article

      Experimental Evaluation of Individualized Treatment Rules

      By: Kosuke Imai and Michael Lingzhi Li
      The increasing availability of individual-level data has led to numerous applications of individualized (or personalized) treatment rules (ITRs). Policy makers often wish to empirically evaluate ITRs and compare their relative performance before implementing them in a... View Details
      Keywords: Causal Inference; Heterogeneous Treatment Effects; Precision Medicine; Uplift Modeling; Analytics and Data Science; AI and Machine Learning
      Citation
      Find at Harvard
      Read Now
      Related
      Imai, Kosuke, and Michael Lingzhi Li. "Experimental Evaluation of Individualized Treatment Rules." Journal of the American Statistical Association 118, no. 541 (2023): 242–256.
      • June 2020
      • Case

      Breakthroughs at Blueprint Medicines

      By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma
      Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details
      Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts
      Citation
      Educators
      Purchase
      Related
      Hamermesh, Richard G., Kathy Giusti, and Susie L. Ma. "Breakthroughs at Blueprint Medicines." Harvard Business School Case 820-001, June 2020.
      • Article

      How Harvard Business School Is Advancing Precision Medicine

      By: Kathy Giusti and Richard G. Hamermesh
      Citation
      Read Now
      Related
      Giusti, Kathy, and Richard G. Hamermesh. "How Harvard Business School Is Advancing Precision Medicine." Journal of Precision Medicine (March 2020).
      • July 2019 (Revised July 2019)
      • Teaching Note

      Intermountain Healthcare: Pursuing Precision Medicine

      By: Richard G. Hamermesh, Robert S. Huckman and Julia Kelley
      Citation
      Purchase
      Related
      Hamermesh, Richard G., Robert S. Huckman, and Julia Kelley. "Intermountain Healthcare: Pursuing Precision Medicine." Harvard Business School Teaching Note 820-019, July 2019. (Revised July 2019.)
      • 2019
      • Chapter

      Characterizing the Drug Development Pipeline for Precision Medicines

      By: Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern
      BOOK ABSTRACT: Personalized and precision medicine (PPM)—the targeting of therapies according to an individual’s genetic, environmental, or lifestyle characteristics—is becoming an increasingly important approach in health care treatment and prevention. The advancement... View Details
      Keywords: Healthcare; Precision Medicine
      Citation
      Related
      Chandra, Amitabh, Craig Garthwaite, and Ariel Dora Stern. "Characterizing the Drug Development Pipeline for Precision Medicines." Chap. 5 in Economic Dimensions of Personalized and Precision Medicine, edited by Ernest R. Berndt, Dana P. Goldman, and John W. Rowe, 115–158. University of Chicago Press, 2019.
      • 28 Feb 2019
      • Interview

      Pursuing Precision Medicine at Intermountain Healthcare

      By: Richard G. Hamermesh and Brian Kenny
      Citation
      Related
      "Pursuing Precision Medicine at Intermountain Healthcare." Cold Call (podcast), Harvard Business Review Group, February 28, 2019.
      • November 12, 2018
      • Article

      Precision Medicine Has Transformed Cancer Treatment. Here's How to Move It Beyond Oncology

      By: Richard G. Hamermesh and Kathy Giusti
      Citation
      Read Now
      Related
      Hamermesh, Richard G., and Kathy Giusti. "Precision Medicine Has Transformed Cancer Treatment. Here's How to Move It Beyond Oncology." Fortune.com (November 12, 2018).
      • October 4, 2018
      • Article

      Precision Medicine Needs a Business Mindset in Order to Flourish

      By: Richard G. Hamermesh and Kathryn E. Giusti
      Citation
      Read Now
      Related
      Hamermesh, Richard G., and Kathryn E. Giusti. "Precision Medicine Needs a Business Mindset in Order to Flourish." STAT (October 4, 2018).
      • September 2017 (Revised February 2023)
      • Case

      Intermountain Healthcare: Pursuing Precision Medicine

      By: Richard G. Hamermesh, Kathy E. Giusti, Robert S. Huckman and Julia Kelley
      Headquartered in Salt Lake City, Intermountain Healthcare operates 23 hospitals and hundreds of clinics in Utah and Idaho and provides insurance to approximately 850,000 patients through its insurance arm, SelectHealth. In 2013, Intermountain, known for its commitment... View Details
      Keywords: Precision Medicine; Healthcare; Innovation; Cancer; Cancer Research; Health Care; Technology; Health Care and Treatment; Innovation Leadership; Disruptive Innovation; Entrepreneurship; Decision Choices and Conditions; Health Industry; Insurance Industry; Utah; United States; North America
      Citation
      Educators
      Purchase
      Related
      Hamermesh, Richard G., Kathy E. Giusti, Robert S. Huckman, and Julia Kelley. "Intermountain Healthcare: Pursuing Precision Medicine." Harvard Business School Case 818-018, September 2017. (Revised February 2023.)
      • April 13, 2017
      • Article

      What Precision Medicine Can Learn from the NFL

      By: Richard G. Hamermesh and Kathryn E. Giusti
      Citation
      Read Now
      Related
      Hamermesh, Richard G., and Kathryn E. Giusti. "What Precision Medicine Can Learn from the NFL." Forbes.com (April 13, 2017).
      • March 17, 2017
      • Article

      How Economics Can Shape Precision Medicines

      By: Ariel Dora Stern, Brian M. Alexander and Amitabh Chandra
      Many public and private efforts in coming years will focus on research in precision medicine, developing biomarkers to indicate which patients are likely to benefit from a certain treatment so that others can be spared the cost—financial and physical—of being treated... View Details
      Keywords: Health Care and Treatment; Research; Economics; Motivation and Incentives
      Citation
      Find at Harvard
      Register to Read
      Related
      Stern, Ariel Dora, Brian M. Alexander, and Amitabh Chandra. "How Economics Can Shape Precision Medicines." Science 355, no. 6330 (March 17, 2017): 1131–1133.
      • Article

      One Obstacle to Curing Cancer: Patient Data Isn't Shared

      By: Richard G. Hamermesh and Kathy Giusti
      Precision Medicine requires large datasets to identify the mutations that lead to various cancers. Currently, genomic information is hoarded in fragmented silos within numerous academic medical centers, pharmaceutical companies, and some disease-based foundations. For... View Details
      Keywords: Healthcare; Technological And Scientific Innovation; Cancer Care In The U.S.; Cancer Treatment; Precision Medicine; Personalized Medicine; Data Sharing; Technological Innovation; Analytics and Data Science; Health Disorders; Medical Specialties; Research and Development; Customization and Personalization; Health Industry; United States
      Citation
      Register to Read
      Related
      Hamermesh, Richard G., and Kathy Giusti. "One Obstacle to Curing Cancer: Patient Data Isn't Shared." Harvard Business Review (website) (November 28, 2016).
      • 1

      Are you looking for?

      →Search All HBS Web
      ǁ
      Campus Map
      Harvard Business School
      Soldiers Field
      Boston, MA 02163
      →Map & Directions
      →More Contact Information
      • Make a Gift
      • Site Map
      • Jobs
      • Harvard University
      • Trademarks
      • Policies
      • Accessibility
      • Digital Accessibility
      Copyright © President & Fellows of Harvard College.